Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Epidemiologie hoofdstuk lezen eerste hoofdstuk lezen

2024 | OriginalPaper | Hoofdstuk

37. Kinderen en jongvolwassenen

Auteurs : Drs. D.T.C. de Winter, Drs. M.S. Mud, Dr. S.J.C.M.M. Neggers, Prof. dr. M.M. van den Heuvel-Eibrink

Gepubliceerd in: Klachten na kanker

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

De overleving van kinderkanker is in de afgelopen decennia toegenomen, mede dankzij verbeterde behandelstrategieën voor kinderen met kanker. Echter, twee derde van de overlevenden van kinderkanker ervaren ten minste één of meerdere nadelige langetermijngevolgen, zoals secundaire tumoren, cardiovasculaire problemen, longproblemen, nierschade, leverschade, gehoorschade, verschillende endocriene late effecten en psychosociale en neurocognitieve problemen. Idealiter wordt overlevenden van kinderkanker geadviseerd om op volwassen leeftijd regelmatig gecontroleerd te worden om langetermijneffecten vroegtijdig op te kunnen sporen en indien nodig en mogelijk te behandelen. Door het stijgende aantal overlevenden van kinderkanker, in absolute zin, krijgen steeds meer huisartsen te maken met deze groep patiënten. Daartoe verdienen langetermijneffecten na behandeling van kinderkanker meer aandacht in de eerste lijn en is het belangrijk de bewustwording te vergroten van de morbiditeit die reeds op relatief jonge leeftijd kan optreden.
vorige hoofdstuk Ervaringsverhaal Jeroen
volgende hoofdstuk Kwetsbare ouderen
Literatuur
1.
Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5–a population-based study. Lancet Oncol. 2014;15(1):35–47.PubMedCrossRef
2.
Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297(24):2705–15.PubMedCrossRef
3.
Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371–81.PubMedPubMedCentralCrossRef
4.
Mueller BA, Doody DR, Weiss NS, Chow EJ. Hospitalization and mortality among pediatric cancer survivors: a population-based study. Cancer Causes Control. 2018;29(11):1047–57.PubMedCrossRef
5.
Dutch Childhood Oncology Group. Richtlijn follow-up na kinderkanker meer dan 5 jaar na diagnose. SKION, Den Haag/Amsterdam; 2010. www.​skion.​nl.
6.
Streefkerk N, Heins M, Tissing W, Korevaar J, Kremer L. Huisartsenzorg bij langetermijnoverlevenden van kinderkanker. Huisarts en wetenschap. 2020;63(3):14–7.CrossRef
7.
Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2328–38.PubMedPubMedCentralCrossRef
8.
Kilsdonk E, Van Dulmen-den BE, Van Leeuwen FE, et al. Late mortality in childhood cancer survivors according to pediatric cancer diagnosis and treatment era in the Dutch LATER cohort. Cancer Invest. 2022;40(5):413–24.PubMedCrossRef
9.
Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001;19(13):3163–72.PubMedCrossRef
10.
Garwicz S, Anderson H, Olsen JH, et al. Late and very late mortality in 5-year survivors of childhood cancer: changing pattern over four decades–experience from the Nordic countries. Int J Cancer. 2012;131(7):1659–66.PubMedCrossRef
11.
Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304(2):172–9.PubMedCrossRef
12.
Erdmann F, Frederiksen LE, Bonaventure A, et al. Childhood cancer: Survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol. 2021;71(Pt B):101733.PubMedCrossRef
13.
Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083–95.PubMedPubMedCentralCrossRef
14.
Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA. 2011;305(22):2311–9.PubMedCrossRef
15.
Olsen JH, Möller T, Anderson H, et al. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst. 2009;101(11):806–13.PubMedCrossRef
16.
Turcotte LM, Liu Q, Yasui Y, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970–2015. JAMA. 2017;317(8):814–24.PubMedPubMedCentralCrossRef
17.
Teepen JC, Van Leeuwen FE, Tissing WJ, et al. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. J Clin Oncol. 2017;35(20):2288–98.PubMedCrossRef
18.
Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927–95.PubMedCrossRef
19.
Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123–36.PubMedPubMedCentralCrossRef
20.
Van Dalen EC, Mulder RL, Suh E, et al. Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Eur J Cancer. 2021;156:127–37.PubMedCrossRef
21.
Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer. 2002;95(11):2431–41.
22.
Mulder RL, Thönissen NM, Van der Pal HJ, et al. Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax. 2011;66(12):1065–71.PubMedCrossRef
23.
Kooijmans ECM, Van der Pal HJH, Pluijm SMF, et al. The Dutch Childhood Cancer Survivor Study (DCCSS)-LATER 2 kidney analysis examined long-term glomerular dysfunction in childhood cancer survivors. Kidney Int. 2022;102(5):1136–46.PubMedCrossRef
24.
Knijnenburg SL, Jaspers MW, Van der Pal HJ, et al. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol. 2012;7(9):1416–27.PubMedPubMedCentralCrossRef
25.
26.
Green DM, Wang M, Krasin M, et al. Kidney function after treatment for childhood cancer: a report from the St. Jude lifetime cohort study. J Am Soc Nephrol. 2021;32(4):983–93.
27.
Dieffenbach BV, Liu Q, Murphy AJ, et al. Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Eur J Cancer. 2021;155:216–26.PubMedPubMedCentralCrossRef
28.
29.
Bardi E, Mulder RL, Van Dalen EC, et al. Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group. Cancer Treat Rev. 2021;100:102296.PubMedCrossRef
30.
Goldsby R, Chen Y, Raber S, et al. Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. Gastroenterology. 2011;140(5):1464-71.e1.PubMedCrossRef
31.
Mulder RL, Kremer LC, Koot BG, et al. Surveillance of hepatic late adverse effects in a large cohort of long-term survivors of childhood cancer: prevalence and risk factors. Eur J Cancer. 2013;49(1):185–93.PubMedCrossRef
32.
Clemens E, De Vries AC, Pluijm SF, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. Eur J Cancer. 2016;69:77–85.PubMedCrossRef
33.
Bass JK, Hua CH, Huang J, et al. Hearing loss in patients who received cranial radiation therapy for childhood cancer. J Clin Oncol. 2016;34(11):1248–55.PubMedPubMedCentralCrossRef
34.
Meijer AJM, Fiocco MF, Janssens GO, et al. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neurooncol Adv. 2020;2(1):vdaa122.
35.
Pearson SE, Caimino C, Shabbir M, Baguley DM. The impact of chemotherapy-induced inner ear damage on quality of life in cancer survivors: a qualitative study. J Cancer Surviv. 2022;16(5):976–87.PubMedCrossRef
36.
Clemens E, Van den Heuvel-Eibrink MM, Mulder RL, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019;20(1):e29–41.PubMedPubMedCentralCrossRef
37.
Meacham L. Endocrine late effects of childhood cancer therapy. Curr Probl Pediatr Adolesc Health Care. 2003;33(7):217–42.PubMedCrossRef
38.
Mulder RL, Kremer LC, Van Santen HM, et al. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev. 2009;35(7):616–32.PubMedCrossRef
39.
Van Iersel L, Li Z, Srivastava DK, et al. Hypothalamic-Pituitary disorders in childhood cancer survivors: prevalence, risk factors and long-term health outcomes. J Clin Endocrinol Metab. 2019;104(12):6101–15.PubMedPubMedCentralCrossRef
40.
Inskip PD, Veiga LHS, Brenner AV, et al. Hyperthyroidism after radiation therapy for childhood cancer: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys. 2019;104(2):415–24.PubMedPubMedCentralCrossRef
41.
Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85(9):3227–32.PubMed
42.
Chemaitilly W, Cohen LE, Mostoufi-Moab S, et al. Endocrine late effects in childhood cancer survivors. J Clin Oncol. 2018;36(21):2153–9.PubMedCrossRef
43.
Chemaitilly W, Li Z, Brinkman TM, et al. Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. Cancer. 2022;128(3):606–14.PubMedCrossRef
44.
Armuand G, Wettergren L, Nilsson J, Rodriguez-Wallberg K, Lampic C. Threatened fertility: a longitudinal study exploring experiences of fertility and having children after cancer treatment. Eur J Cancer Care (Engl). 2018;27(2):e12798.PubMedCrossRef
45.
Mulder RL, Font-Gonzalez A, Hudson MM, et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e45–56.PubMedCrossRef
46.
Skinner R, Mulder RL, Kremer LC, et al. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncol. 2017;18(2):e75–90.PubMedCrossRef
47.
Littley MD, Shalet SM, Beardwell CG. Radiation and hypothalamic-pituitary function. Baillieres Clin Endocrinol Metab. 1990;4(1):147–75.PubMedCrossRef
48.
Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St. Jude lifetime cohort study. J Clin Oncol. 2015;33(5):492–500.PubMedPubMedCentralCrossRef
49.
Van der Perk MEM, Van der Kooi ALF, Bos AME, et al. Oncofertility perspectives for Girls with cancer. J Pediatr Adolesc Gynecol. 2022;35(5):523–6.PubMedCrossRef
50.
Mulder RL, Font-Gonzalez A, Green DM, et al. Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e57–67.PubMedCrossRef
51.
52.
Van der Kooi ALF, Mulder RL, Hudson MM, et al. Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Am J Obstet Gynecol. 2021;224(1):3–15.PubMedCrossRef
53.
De Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010;11(2):193–203.PubMedCrossRef
54.
Smith WA, Li C, Nottage KA, et al. Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude lifetime cohort study. Cancer. 2014;120(17):2742–50.PubMedCrossRef
55.
Pluimakers VG, Van Waas M, Neggers S, Van den Heuvel-Eibrink MM. Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors. Crit Rev Oncol Hematol. 2019;133:129–41.PubMedCrossRef
56.
Van Waas M, Neggers SJ, Pieters R, Van den Heuvel-Eibrink MM. Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. Ann Oncol. 2010;21(5):1121–6.PubMedCrossRef
57.
Van Atteveld JE, De Winter DTC, Pluimakers VG, et al. Risk and determinants of low and very low bone mineral density and fractures in a national cohort of Dutch adult childhood cancer survivors (DCCSS-LATER): a cross-sectional study. Lancet Diabetes Endocrinol. 2023;11(1):21–32.PubMedCrossRef
58.
Van Atteveld JE, Pluijm SMF, Ness KK, et al. Prediction of low and very low bone mineral density among adult survivors of childhood cancer. J Clin Oncol. 2019;37(25):2217–25.PubMedPubMedCentralCrossRef
59.
Den Hoed MA, Klap BC, Te Winkel ML, et al. Bone mineral density after childhood cancer in 346 long-term adult survivors of childhood cancer. Osteoporos Int. 2015;26(2):521–9.CrossRef
60.
Van Atteveld JE, Mulder RL, Van den Heuvel-Eibrink MM, et al. Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes Endocrinol. 2021;9(9):622–37.PubMedPubMedCentralCrossRef
61.
Ness KK, Krull KR, Jones KE, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St. Jude lifetime cohort study. J Clin Oncol. 2013;31(36):4496–503.PubMedPubMedCentralCrossRef
62.
Williams AM, Krull KR, Howell CR, et al. Physiologic frailty and neurocognitive decline among young-adult childhood cancer survivors: a prospective study from the St. Jude lifetime cohort. J Clin Oncol. 2021;39(31):3485–95.PubMedPubMedCentralCrossRef
63.
Delaney A, Howell CR, Krull KR, et al. Progression of frailty in survivors of childhood cancer: a St. Jude lifetime cohort report. J Natl Cancer Inst. 2021;113(10): 1415–21.
64.
Brinkman TM, Li C, Vannatta K, et al. Behavioral, social, and emotional symptom comorbidities and profiles in adolescent survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2016;34(28):3417–25.PubMedPubMedCentralCrossRef
65.
Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2396–404.PubMedPubMedCentralCrossRef
66.
Van Gorp M, Van Erp LME, Maas A, et al. Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study. Cancer. 2022;128(5):1074–84.PubMedCrossRef
67.
Langeveld NE, Grootenhuis MA, Voûte PA, De Haan RJ, Van den Bos C. Quality of life, self-esteem and worries in young adult survivors of childhood cancer. Psychooncology. 2004;13(12):867–81.PubMedCrossRef
68.
Zeltzer LK, Lu Q, Leisenring W, et al. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2008;17(2):435–46.PubMedCrossRef
69.
Krull KR, Okcu MF, Potter B, et al. Screening for neurocognitive impairment in pediatric cancer long-term survivors. J Clin Oncol. 2008;26(25):4138–43.PubMedCrossRef
70.
Krull KR, Hardy KK, Kahalley LS, Schuitema I, Kesler SR. Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. J Clin Oncol. 2018;36(21):2181–9.PubMedPubMedCentralCrossRef
71.
Mulrooney DA, Ness KK, Neglia JP, et al. Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the childhood cancer survivor study (CCSS). Sleep. 2008;31(2):271–81.PubMedPubMedCentralCrossRef
72.
Jóhannsdóttir IM, Hjermstad MJ, Moum T, et al. Increased prevalence of chronic fatigue among survivors of childhood cancers: a population-based study. Pediatr Blood Cancer. 2012;58(3):415–20.PubMedCrossRef
73.
Christen S, Roser K, Mulder RL, et al. Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. J Cancer Surviv. 2020;14(6):923–38.PubMedPubMedCentralCrossRef
74.
Michel G, Brinkman TM, Wakefield CE, Grootenhuis M. Psychological outcomes, health-related quality of life, and neurocognitive functioning in survivors of childhood cancer and their parents. Pediatr Clin North Am. 2020;67(6):1103–34.PubMedCrossRef
75.
Van Gorp M, Joosten MMH, Maas A, et al. Psychosocial functioning of parents of Dutch long-term survivors of childhood cancer. Psychooncology. 2023;32(2):283–94.PubMedCrossRef
76.
Buchbinder D, Casillas J, Krull KR, et al. Psychological outcomes of siblings of cancer survivors: a report from the Childhood Cancer Survivor Study. Psychooncology. 2011;20(12):1259–68.PubMedCrossRef
Metagegevens
Titel
Kinderen en jongvolwassenen
Auteurs
Drs. D.T.C. de Winter
Drs. M.S. Mud
Dr. S.J.C.M.M. Neggers
Prof. dr. M.M. van den Heuvel-Eibrink
Copyright
2024
Uitgeverij
Bohn Stafleu van Loghum
Boek
Klachten na kanker

Print ISBN: 978-90-368-3022-5

Elektronisch ISBN: 978-90-368-3023-2

Copyright: 2024

DOI
https://doi.org/10.1007/978-90-368-3023-2_37